Provided are anti-FGFR2b antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

Provided herein are antibodies that specifically bind Tau and methods of using the same.

The present invention relates to bispecific antibodies having activity against a vascular endothelial growth factor (VEGF) and an angiopoietin (ANG), and methods of making and using such bispecific antibodies.

Described herein are materials and methods of incorporating CLIP peptide into the peptide binding groove of HLA Class II antigens and using such HLA Class II antigens for the detection of alloantibodies.

The invention relates to a gene construct comprising at least two nucleic acid sequences, wherein one of the nucleic acid sequences encodes FAH and a second nucleic acid sequence encodes a protein to be produced. This makes it possible to use FAH as a selection marker for the production of recombinant proteins, in particular antibodies. The invention further relates to plasmids, vectors or hepatocytes comprising the gene construct. Furthermore, the invention relates to a method for producing recombinant proteins in FAH(−/−) non-human mammals using the gene construct and FAH as a selection marker.

This invention relates to anti-ROR1 antibodies and methods of using them in treating diseases and conditions related to ROR1 activity, e.g., cancer.

The invention relates to the field of immunity against Coronaviruses. In this respect, the invention provides vectorized antigens derived from Coronaviruses that trigger an immune response against Coronaviruses. The invention accordingly relates to an active ingredient which is a live attenuated recombinant measles virus expressing Coronavirus antigen(s) and to its use in eliciting immunity, in particular protective immunity against SARS-CoV-2 strain and advantageously broad-spectrum protective immunity against various strains of Coronaviruses.

Provided are anti-PD-1 antibodies or fragments thereof. In various example, the antibodies or fragments thereof includes a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer, infection or immune disorders are also provided.

The present invention provides an approach to enhancing the production of a foreign protein serving as a protein-based pharmaceutical product in host cells such as cultured cells derived from a mammal. The present invention provides transformed cells having a novel Hspa5 gene promoter, and a method for secreting and producing a foreign protein at high levels using the transformed host cells.

The invention provides bispecific antibodies binding to human carcinoembryonic antigen CEACAM5 and human CD47, polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further provides methods for selecting and producing such antibodies and methods of using such antibodies in the treatment of diseases in monotherapy as well in combination.